Education
About Us
Working with TipRanks
Follow Us
Qyuns Therapeutics Co., Ltd. Class H (HK:2509)
:2509
RESEARCH TOOLSreports
Total Valuation
Qyuns Therapeutics Co., Ltd. Class H has a market cap or net worth of ―. The enterprise value is HK$3.45B.
Market Cap―
Enterprise ValueHK$3.45B
Share Statistics
Qyuns Therapeutics Co., Ltd. Class H has 227,071,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding227,071,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Qyuns Therapeutics Co., Ltd. Class H’s return on equity (ROE) is -1.47 and return on invested capital (ROIC) is -42.63%.
Return on Equity (ROE)-1.47
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-42.63%
Return on Capital Employed (ROCE)-0.59
Revenue Per Employee468.42K
Profits Per Employee-989.89K
Employee Count339
Asset Turnover0.16
Inventory Turnover19.96
Valuation Ratios
The current PE Ratio of Qyuns Therapeutics Co., Ltd. Class H is ―. Qyuns Therapeutics Co., Ltd. Class H’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value6.64
Price to FCF0.00
Price to Operating Cash Flow-16.32
PEG Ratio―
Income Statement
In the last 12 months, Qyuns Therapeutics Co., Ltd. Class H had revenue of 158.79M and earned -335.57M in profits. Earnings per share was -1.53.
Revenue158.79M
Gross Profit92.19M
Operating Income-326.37M
Pretax Income-349.76M
Net Income-335.57M
EBITDA-311.82M
Earnings Per Share (EPS)-1.53
Cash Flow
In the last 12 months, operating cash flow was -186.09M and capital expenditures 0.00, giving a free cash flow of -186.09M billion.
Operating Cash Flow-186.09M
Free Cash Flow-186.09M
Free Cash Flow per Share-0.82
Dividends & Yields
Qyuns Therapeutics Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.43
52-Week Price Change18.19%
50-Day Moving Average19.02
200-Day Moving Average11.94
Relative Strength Index (RSI)64.05
Average Volume (3m)806.77K
Important Dates
Qyuns Therapeutics Co., Ltd. Class H upcoming earnings date is Mar 27, 2026, Before Open (Confirmed).
Last Earnings DateAug 15, 2025
Next Earnings DateMar 27, 2026
Ex-Dividend Date―
Financial Position
Qyuns Therapeutics Co., Ltd. Class H as a current ratio of 1.43, with Debt / Equity ratio of 230.41%
Current Ratio1.43
Quick Ratio1.43
Debt to Market Cap0.35
Net Debt to EBITDA-0.54
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Qyuns Therapeutics Co., Ltd. Class H has paid 73.00K in taxes.
Income Tax73.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Qyuns Therapeutics Co., Ltd. Class H EV to EBITDA ratio is -5.41, with an EV/FCF ratio of -9.07.
EV to Sales10.63
EV to EBITDA-5.41
EV to Free Cash Flow-9.07
EV to Operating Cash Flow-9.07
Balance Sheet
Qyuns Therapeutics Co., Ltd. Class H has HK$556.55M in cash and marketable securities with HK$527.60M in debt, giving a net cash position of -HK$28.96M billion.
Cash & Marketable SecuritiesHK$556.55M
Total DebtHK$527.60M
Net Cash-HK$28.96M
Net Cash Per Share-HK$0.13
Tangible Book Value Per ShareHK$0.99
Margins
Gross margin is 58.06%, with operating margin of -205.53%, and net profit margin of -211.33%.
Gross Margin58.06%
Operating Margin-205.53%
Pretax Margin-220.26%
Net Profit Margin-211.33%
EBITDA Margin-196.37%
EBIT Margin-215.56%
Analyst Forecast
The average price target for Qyuns Therapeutics Co., Ltd. Class H is HK$26.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetHK$26.00
Price Target Upside-0.46% Downside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―